Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Camilla S Graham

Showing results (1-10 of 34) with videos related to

Pageof 4
Sort By:
Clinical Liver Disease|July 28, 2020
The Current Status of US and Global Access to Direct-Acting Antiviral Regimens for Hepatitis C Virus InfectionCamilla S Graham
JAMA|February 24, 2015
Hepatitis C and HIV co-infection: closing the gapsCamilla S Graham
Annals of Internal Medicine|April 25, 2017
Making Do With What We HaveCamilla S Graham
JAMA|March 3, 2020
Universal Screening for Hepatitis C Virus Infection: A Step Toward EliminationCamilla S Graham, Stacey Trooskin
Antiviral Research|January 24, 2015
A path to eradication of hepatitis C in low- and middle-income countriesCamilla S Graham, Tracy Swan
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|January 23, 2003
First things first: balancing hepatitis C and human immunodeficiency virusCamilla S Graham, Margaret James Koziel
Infectious Agents and Cancer|May 18, 2016
Price and affordability of direct-acting antiviral regimens for hepatitis C virus in the United StatesElana S Rosenthal, Camilla S Graham
Infectious Disease Clinics of North America|May 21, 2018
Removing the Barriers from the Path to Eliminate Hepatitis CCamilla S Graham, Stacey B Trooskin
American Journal of Respiratory and Critical Care Medicine|June 9, 2026
Reply to Sun et al.: Interpreting Benefit in ELEVATE-IPFToby Maher, Mark J Hamblin, Camilla S Graham, et al.
American Journal of Public Health|July 21, 2012
Comparison of current US risk strategy to screen for hepatitis C virus with a hypothetical targeted birth cohort strategyKenneth J Tomaszewski, Baris Deniz, Peter Tomanovich, et al.
Pageof 4

Showing results (1-10 of 34) with videos related to

Sort By:
Pageof 4
Clinical Liver Disease|July 28, 2020
The Current Status of US and Global Access to Direct-Acting Antiviral Regimens for Hepatitis C Virus InfectionCamilla S Graham
JAMA|February 24, 2015
Hepatitis C and HIV co-infection: closing the gapsCamilla S Graham
Annals of Internal Medicine|April 25, 2017
Making Do With What We HaveCamilla S Graham
JAMA|March 3, 2020
Universal Screening for Hepatitis C Virus Infection: A Step Toward EliminationCamilla S Graham, Stacey Trooskin
Antiviral Research|January 24, 2015
A path to eradication of hepatitis C in low- and middle-income countriesCamilla S Graham, Tracy Swan
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|January 23, 2003
First things first: balancing hepatitis C and human immunodeficiency virusCamilla S Graham, Margaret James Koziel
Infectious Agents and Cancer|May 18, 2016
Price and affordability of direct-acting antiviral regimens for hepatitis C virus in the United StatesElana S Rosenthal, Camilla S Graham
Infectious Disease Clinics of North America|May 21, 2018
Removing the Barriers from the Path to Eliminate Hepatitis CCamilla S Graham, Stacey B Trooskin
American Journal of Respiratory and Critical Care Medicine|June 9, 2026
Reply to Sun et al.: Interpreting Benefit in ELEVATE-IPFToby Maher, Mark J Hamblin, Camilla S Graham, et al.
American Journal of Public Health|July 21, 2012
Comparison of current US risk strategy to screen for hepatitis C virus with a hypothetical targeted birth cohort strategyKenneth J Tomaszewski, Baris Deniz, Peter Tomanovich, et al.
Pageof 4